Chemotherapy Toxicity Predictive Model Validated

This article originally appeared here.
Share this content:
Chemotherapy Toxicity Predictive Model Validated
Chemotherapy Toxicity Predictive Model Validated

WEDNESDAY, May 25, 2016 (HealthDay News) -- A predictive model for chemotherapy toxicity has been validated for older patients with solid tumors, according to a study published online May 16 in the Journal of Clinical Oncology.

Arti Hurria, M.D., from the City of Hope Comprehensive Cancer Center in Duarte, Calif., and colleagues developed a predictive model for chemotherapy toxicity in a cohort of 500 patients aged 65 years or older, with a solid tumor, who were scheduled to receive a new chemotherapy regimen. The model consisted of geriatric assessment questions and other clinical variables. The model was externally validated in an independent cohort of 250 patients (mean age, 73 years).

The researchers found that 58 percent of patients experienced toxicity of grade 3 or higher. There was an increase in the risk of toxicity with increasing risk score (36.7, 62.4, and 70.2 percent for low, medium, and high risk respectively; P < 0.001). The area under the receiver-operating characteristic curve was 0.65, which did not differ significantly from that of the development cohort (0.72; P = 0.09). No correlation was seen for Karnofsky Performance Status and chemotherapy toxicity (P = 0.25).

"This study externally validated a chemotherapy toxicity predictive model for older adults with cancer," the authors write. "This predictive model should be considered when discussing the risks and benefits of chemotherapy with older adults."

Several authors disclosed financial ties to the biopharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »